KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers by rpadmin | Feb 17, 2022 | Kahr, PR Newswire
KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR’s Lead Anti-CD47 Candidate in Blood Cancers by rpadmin | May 26, 2021 | Kahr, PR Newswire
Focus Fund and MD Anderson Launch Investment Fund to Support Promising Investigational Cancer Therapies in Early-Stage Clinical Trials by rpadmin | Oct 20, 2020 | PR Newswire